Philip Bonomi to Administration, Oral
This is a "connection" page, showing publications Philip Bonomi has written about Administration, Oral.
Connection Strength
0.130
-
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
Score: 0.061
-
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report. Semin Oncol. 1995 Aug; 22(4 Suppl 9):42-7.
Score: 0.033
-
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16.
Score: 0.024
-
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1995 Jul; 13(7):1615-22.
Score: 0.008
-
Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
Score: 0.004